Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 28, 2016; 8(9): 421-438
Published online Mar 28, 2016. doi: 10.4254/wjh.v8.i9.421
New advances in hepatocellular carcinoma
Sonia Pascual, Iván Herrera, Javier Irurzun
Sonia Pascual, Iván Herrera, Javier Irurzun, Liver Unit, Gastroenterology Department, Interventional Radiological Unit, Hospital General Universitario de Alicante, 03010 Alicante, Spain
Author contributions: Pascual S, Herrera I and Irurzun J contributed equally to this work; Pascual S designed the research; Pascual S, Herrera I and Irurzun J wrote the paper.
Conflict-of-interest statement: None of the authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content or the paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Sonia Pascual, MD, Liver Unit, Gastroenterology Department, Interventional Radiological Unit, Hospital General Universitario de Alicante, C/Pintor Baeza s/n, 03010 Alicante, Spain. pascual_son@gva.es
Telephone: +34-965-934466 Fax: +34-965-934468
Received: April 29, 2015
Peer-review started: May 7, 2015
First decision: September 8, 2015
Revised: March 6, 2016
Accepted: March 14, 2016
Article in press: March 16, 2016
Published online: March 28, 2016
Core Tip

Core tip: Liver cancer is the fifth leading cause of cancer worldwide, and the third-leading cause of cancer death. Altouhg some risk factors have been classically associated with development of hepatocellular carcinoma (HCC), in the last years, also, some protective factors have been described, like coffee drink, and drugs like statins and beta-blockers. The current European Association for the Study of Liver and American Association for the Study of Liver Diseases guidelines recomended the barcelona clinic liver cancer classification as staging system for prognosis prediction and treatment allocation The therapeutic approach in patients with HCC depends on factors such as liver function, tumour extension and comorbidities existence. Available treatments are: Surgical treatments, percutaneous ablation, chemoembolization, radioembolization and systemic treatment.